L. M. Azzarano

发表

Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.

K. Ward, B. R. Smith, R. Keenan, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.

K. Ward, K. Erhard, R. Calvo, 2000, Journal of medicinal chemistry.

Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.

B. Smith, K. Ward, J. Kehler, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Preclinical Pharmacokinetic Properties of the P-Glycoprotein Inhibitor GF120918A (HCl salt of GF120918, 9,10-Dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the Mouse, Rat, Dog, and Monkey

K. Ward, L. M. Azzarano, 2004, Journal of Pharmacology and Experimental Therapeutics.

Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. II. Studies implicating transporter-mediated intestinal secretion

K. Ward, B. R. Smith, J. Kehler, 2004, Xenobiotica; the fate of foreign compounds in biological systems.

Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin αvβ3) antagonists

K. Ward, R. Willette, T. Yue, 2003 .

Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

K. Erhard, R. Keenan, M. Lark, 1999, Bioorganic & medicinal chemistry letters.

Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase

K. Ward, B. R. Smith, J. Mumaw, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

SB-239063, a Potent and Selective Inhibitor of P38 Map Kinase: Preclinical Pharmacokinetics and Species-Specific Reversible Isomerization

B. Smith, K. Ward, L. M. Azzarano, 2001, Pharmaceutical Research.

Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.

K. Ward, H. Sarau, J. Foley, 2007, Bioorganic & medicinal chemistry letters.

Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors.

Baoguang Zhao, M. Head, N. Laping, 2009, Bioorganic & medicinal chemistry letters.

SB-242235, a selective inhibitor of p38 mitogenactivated protein kinase. I: Preclinical pharmacokinetics

K. Ward, B. R. Smith, L. M. Azzarano, 2002, Xenobiotica; the fate of foreign compounds in biological systems.

Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens.

Nagesh R Palepu, B. Smith, L. M. Azzarano, 2003, International journal of pharmaceutics.

Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations

K. Ward, B. R. Smith, L. M. Azzarano, 2004, Xenobiotica; the fate of foreign compounds in biological systems.

Improving the developability profile of pyrrolidine progesterone receptor partial agonists.

C. Duraiswami, N. Laping, Shawn P. Williams, 2010, Bioorganic & medicinal chemistry letters.